Clinical Trial

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Protocol Amendment History 7 changes
notable Trial sites expanded: 68 -> 78 locations 2026-06-25
notable Primary completion moved earlier: 2027-09-25 -> 2027-06-25 2026-06-25
minor Completion moved earlier: 2028-03-23 -> 2027-11 2026-06-25
notable Primary completion pushed: 2027-06 -> 2027-09-25 2026-06-23
minor Completion pushed: 2027-11 -> 2028-03-23 2026-06-23
notable Trial sites expanded: 43 -> 68 locations 2026-06-05
notable Trial sites expanded: 38 -> 43 locations 2026-03-31
Trial Details
NCT Number NCT07215390
Lead Sponsor Apellis Pharmaceuticals, Inc.
Conditions Geographic Atrophy Secondary to Age-related Macular Degeneration
Enrollment 240 participants
Start Date 2025-06-23
Primary Completion 2027-06-25 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-24